p53 and brain tumors: From gene mutations to gene therapy

被引:62
作者
Fulci, G
Ishii, N
Van Meir, EG
机构
[1] Emory Univ, Winship Canc Ctr, Mol Neurooncol Lab, Atlanta, GA 30322 USA
[2] CHU Vaudois, Dept Neurosurg, Lab Tumor Biol & Genet, Univ Hosp, CH-1011 Lausanne, Switzerland
[3] Emory Univ, Dept Neurol Surg, Mol Neurooncol Lab, Atlanta, GA 30322 USA
关键词
D O I
10.1111/j.1750-3639.1998.tb00187.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The p53 tumor suppressor gene (TP53) is the most frequently altered gene in human cancer and is also found mutated in several types of brain tumors, Loss of p53 function plays a central role in the development of cancer, The characterization of the biochemical pathways by which p53 alteration triggers tumorigenesis is the foundation for the design of novel therapeutic approaches. Investigations of the intracellular mechanisms at the origin of p53 tumor suppressive functions have shown that p53 is a transcription factor able to sense a variety of cellular insults and induce a dual response: cell growth arrest/senescence or apoptosis. Less well studied are p53's influences on extracellular events such as tumor angiogenesis, immunology and invasion. Here, we review these findings and specifically discuss their implications for brain tumor genesis, molecular diagnosis and prognosis, Of clinical importance are the findings that brain tumors with wild type (wt) or mutant p53 status may respond differently to radiation therapy and that novel therapeutic strategies using TP53 gene transfer or specifically targeting tumor cells with mutated p53 are being evaluated in clinical trials,
引用
收藏
页码:599 / 613
页数:15
相关论文
共 134 条
  • [1] GROWTH-INHIBITION OF RAT GLIOMA-CELLS IN-VITRO AND IN-VIVO BY ASPIRIN
    AAS, AT
    TONNESSEN, TI
    BRUN, A
    SALFORD, LG
    [J]. JOURNAL OF NEURO-ONCOLOGY, 1995, 24 (02) : 171 - 180
  • [2] P53 CONTROLS BOTH THE G(2)/M AND THE G(1) CELL-CYCLE CHECKPOINTS AND MEDIATES REVERSIBLE GROWTH ARREST IN HUMAN FIBROBLASTS
    AGARWAL, ML
    AGARWAL, A
    TAYLOR, WR
    STARK, GR
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (18) : 8493 - 8497
  • [3] Genetic instability leads to loss of both p53 alleles in a human glioblastoma
    Albertoni, M
    Daub, DM
    Arden, KC
    Viars, CS
    Powell, C
    Van Meir, EG
    [J]. ONCOGENE, 1998, 16 (03) : 321 - 326
  • [4] ALI IU, 1994, CANCER RES, V54, P1
  • [5] NEGATIVE EFFECTS OF WILD-TYPE P53 AND S-MYC ON CELLULAR GROWTH AND TUMORIGENICITY OF GLIOMA-CELLS - IMPLICATION OF THE TUMOR-SUPPRESSOR GENES FOR GENE-THERAPY
    ASAI, A
    MIYAGI, Y
    SUGIYAMA, A
    GAMANUMA, M
    ILHONG, S
    TAKAMOTO, S
    NOMURA, K
    MATSUTANI, M
    TAKAKURA, K
    KUCHINO, Y
    [J]. JOURNAL OF NEURO-ONCOLOGY, 1994, 19 (03) : 259 - 268
  • [6] Recruitment of p300/CBP in p53-dependent signal pathways
    Avantaggiati, ML
    Ogryzko, V
    Gardner, K
    Giordano, A
    Levine, AS
    Kelly, K
    [J]. CELL, 1997, 89 (07) : 1175 - 1184
  • [7] ADENOVIRUS-MEDIATED P53 GENE DELIVERY INHIBITS 9L GLIOMA GROWTH IN RATS
    BADIE, B
    DRAZAN, KE
    KRAMAR, MH
    SHAKED, A
    BLACK, KL
    [J]. NEUROLOGICAL RESEARCH, 1995, 17 (03) : 209 - 216
  • [8] Ex vivo expansion of tumor-draining lymph node cells using compounds which activate intracellular signal transduction .1. Characterization and in vivo anti-tumor activity of glioma-sensitized lymphocytes
    Baldwin, NG
    Rice, CD
    Tuttle, TM
    Bear, HD
    Hirsch, JI
    Merchant, RE
    [J]. JOURNAL OF NEURO-ONCOLOGY, 1997, 32 (01) : 19 - 28
  • [9] BECKMAN WC, 1987, CANCER-AM CANCER SOC, V59, P266, DOI 10.1002/1097-0142(19870115)59:2<266::AID-CNCR2820590215>3.0.CO
  • [10] 2-6